Connect with us

Technology

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

Published

on

Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the added benefits of elebsiran towards achieving a higher rate of HBsAg loss in combination with PEG-IFNα

DURHAM, N.C. and BEIJING, China, March 30, 2025 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.

ENSURE (NCT05970289) is a multicenter, open-label Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), in combination with pegylated interferon alpha (PEG-IFNα) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU/mL. Participants who completed 9 doses of BRII-179, a recombinant protein-based therapeutic vaccine, in combination with elebsiran (BRII-835) in a previous APAC study BRII-179-835-001 (NCT04749368) were enrolled to Cohort 4 of this study and received elebsiran and PEG-IFNα combination treatment. The design of Cohort 4 as part of this study was based on insight from previous studies that a significant proportion of the chronic HBV patients fail to generate a sufficient immune response after receiving multiple doses of BRII-179, and therefore unlikely to have the immune support to achieve sustainable functional cure.

Emerging data from Cohort 4 showed that participants who previously had BRII-179 induced anti-HBs response achieved a substantially higher rate of HBsAg seroclearance than those who did not. At Week 24, more than half of the BRII-179 responders (55.6% [10/18]) achieved HBsAg seroclearance, compared to only 10.0% (1/10) in non-responders. These latest data suggest that BRII-179 can serve as a predictive tool for enriching patients more likely to respond to curative therapies.

Additional data from Cohorts 1-3 of the ENSURE study showed that higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants receiving elebsiran in combination with PEG-IFNα than those receiving PEG-IFNα alone.  

“The positive Cohort 4 data from the ENSURE study opens new doors for HBV functional cure,” said Dr. Grace Lai-Hung Wong, Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China. “Previous studies have suggested that BRII-179 may offer a unique opportunity to identify CHB patients who are able to elicit the necessary HBsAg antibody response. I believe these new findings provide clear evidence supporting such value proposition and further substantiate the role of BRII-179 in shaping future combination therapies.”

“We are encouraged that the Cohort 4 from the ENSURE study continue to support our enrichment strategy in developing a functional cure for chronic HBV in target populations,” said David Margolis, MD, Chief Medical Officer of Brii Bio. “The results underscore the potential of BRII-179 in identifying patients who are more likely to respond to regimens aimed at functional cure, thereby enhancing functional cure rates in the target population while reducing exposure to costly therapies for those with a lower probability of cure. We are committed to advancing BRII-179 in combination with various modalities through our ongoing studies and collaborations with strategic partners, aiming to deliver higher functional cure rates to 254 million patients worldwide living with chronic HBV infection.”

Abstract Number: OP0335

Presentation Title: Responders to Prior BRII-179 Treatment Achieved Faster and Higher Rate of HBsAg Seroclearance Following Treatment of Elebsiran and PEG-IFNα in Participants with Chronic Hepatitis B Virus Infection: Preliminary Data from ENSURE Study

Presenter: Grace Lai-Hung Wong, MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine), Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China

Among the 28 of the 31 participants enrolled in Cohort 4 with baseline HBsAg ≥ 100 IU/mL being analyzed, 18 participants with peak anti-HBs ≥ 10 IU/L induced by prior BRII-179 treatment were defined as BRII-179 responders and 10 participants with peak anti-HBs < 10 IU/L were defined as non-responders.At Week 24 of treatment with elebsiran + PEG-IFNα, 39.3% (11/28) of the Cohort 4 participants achieved HBsAg seroclearance.The rate of HBsAg seroclearance at Week 24 in the BRII-179 responders was 55.6% (10/18), notably higher compared to the non-responders at 10% (1/10).Responders to prior BRII-179 treatment appeared to achieve a faster HBsAg seroclearance compared to BRII-179 naïve participants receiving elebsiran + PEG-IFNα as previously reported.Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection.Treatment with elebsiran + PEG-IFNα is ongoing for 48 weeks.

Abstract Number: LB0009

Presentation Title: Higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants with chronic HBV infection receiving elebsiran (BRII-835) and pegylated interferon alfa-2a (PEG-IFNα) compared to PEG-IFNα alone: Week 48 results from ongoing ENSURE study

Presenter: Jidong Jia, M.D., Ph.D., Professor of Medicine at the Liver Research Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China

The rates of HBsAg seroclearance at EOT in elebsiran 200 mg + PEG-IFNα and elebsiran 100 mg + PEG-IFNα cohorts were 26.3% (5/19) and 33.3% (6/18), respectively, notably higher compared to PEG-IFNα alone cohort (5.6%) in participants with baseline HBsAg levels 100-3,000 IU/mL.Greater HBsAg reductions at EOT were observed in elebsiran + PEG-IFNα combination cohorts (mean [SE]: -2.47 [0.28] or -3.01 [0.28] log10 IU/mL in elebsiran 200 mg or 100 mg, respectively) than in PEG-IFNα cohort (-1.02 [0.30] log10 IU/mL).Elebsiran in combination with PEG-IFNα at both 200 mg and 100 mg doses achieved similar HBsAg reductions and seroclearance rates. Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection.Post-treatment follow-up is ongoing and will continue for 24 weeks after discontinuation of treatment.

As part of Brii Bio’s unique approach to developing a functional cure for HBV, the Company and its partners are actively progressing multiple combination studies with our differentiated portfolio, including BRII-179, a recombinant protein-based HBV immunotherapeutic being evaluated in multiple combination studies with elebsiran led by Brii Bio; elebsiran being evaluated in combination with PEG-IFNα  in studies led by Brii Bio and tobevibart, an investigational broadly neutralizing monoclonal antibody targeting HBV, being evaluated  in multiple Phase 2 and 3 tobevibart and elebsiran combination studies led by Vir Biotechnology. Key data readouts will be shared in the coming months at the scientific conferences throughout 2025.

About Hepatitis B

Hepatitis B virus (HBV) infection is one of the world’s most significant infectious disease threats with more than 254 million people infected globally.[1] Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.[1] HBV is of exceptional concern in China, where 87 million people are chronically infected.[2]

About BRII-179

BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration (the “NMPA”) granted BRII-179 Breakthrough Therapy Designation.

About Elebsiran (BRII-835, VIR-2218)

Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. Brii Bio licensed exclusive rights to develop and commercialize elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020.

About Brii Bio

Brii Biosciences Limited (“Brii Bio“, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.

[1] World Health Organization. (April 2024). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from https://www.who.int/publications/i/item/9789240091672

[2] World Health Organization. Hepatitis. World Health Organization. Retrieved from https://www.who.int/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/brii-bio-unveils-new-data-from-its-ongoing-phase-2-ensure-study-at-apasl-2025-showcasing-brii-179s-unique-potential-to-prime-and-boost-higher-hbsag-loss-through-target-patient-identification-302415033.html

SOURCE Brii Biosciences Limited

Continue Reading

Technology

CollectivIQ Introduces GigaBrain, Giving Enterprises a Shared Brain That Gets Smarter as Employees Work

Published

on

By

New Enterprise Intelligence Layer Turns the Collective Learnings of AI Agents Into Secure, Usable Organizational Knowledge

BOSTON, Oct. 21, 2026 /PRNewswire/ — CollectivIQ, the collective intelligence platform built to give employees more honest AI insights and digital teammates that put its intelligence to work, today announced the availability of GigaBrain, a new shared intelligence layer that enables organizations to capture, connect, and use the knowledge accumulated by employees and their Digital Direct Reports (DDRs), which are specialized AI teammates that work for people much like human direct reports do. Every company has valuable knowledge that lives outside its formal systems, across various tools, residing in employees’ heads, embedded in conversations, and lodged in disparate company applications. GigaBrain is designed to make that collective intelligence available to the organization and its employees.

As employees work with their Digital Direct Reports, those AI teammates develop context about their work, including projects, processes, responsibilities, relationships, and preferences. With GigaBrain, those individual learnings can contribute to a shared enterprise memory, allowing knowledge developed in one part of an organization to make AI more useful across the business. The result is an enterprise AI environment that gets smarter through use. Rather than requiring employees to repeatedly find, upload or explain the same information, GigaBrain gives employees and their Digital Direct Reports access to relevant organizational context when they need it.

When a sales representative’s DDR learns the intricacies of a customer’s procurement process, including approval requirements, key decision-makers, and purchasing timelines, that knowledge can automatically become available to other team members, subject to appropriate access permissions. When the customer reaches out for help, the team will already have the context needed to navigate the relationship effectively, without asking the customer to repeat information or relying on a manual handoff.

“Companies are collectively spending billions to bring intelligence to their employees, but very little of that investment makes the company itself smarter,” said John Davie, CEO of CollectivIQ. “The breakthrough isn’t just giving every employee an AI teammate, it’s making sure what those employees and AI teammates learn becomes an advantage for the entire organization. GigaBrain turns everyday work into intelligence that compounds across the enterprise.”

While enterprise AI platforms such as Microsoft Copilot and Glean help employees access organizational information, GigaBrain is designed to capture knowledge that emerges through employees’ day-to-day interactions with their DDRs, including insights that may never be formally documented. GigaBrain creates an organizational knowledge layer that can connect what employees and their Digital Direct Reports learn through everyday work, giving AI access to relevant internal context alongside the broader knowledge available from large language models.

GigaBrain was built to provide a source of enterprise knowledge that Digital Direct Reports can draw upon as they work, including the ability to trace information back to its source, giving employees greater visibility into where organizational knowledge came from, and helping AI work from relevant company context. Employees do not need to manually document every useful insight for the system to become more valuable. As they collaborate with their Digital Direct Reports, relevant knowledge can become part of the enterprise intelligence available to other authorized AI teammates.

GigaBrain is also designed for the realities of enterprise information governance, as employees can use an incognito mode when working with information that should not contribute to shared organizational memory, giving users a way to keep sensitive or confidential interactions out of GigaBrain.

GigaBrain expands CollectivIQ’s vision for Digital Direct Reports beyond individual AI productivity, allowing the knowledge developed through that work to become part of a broader organizational intelligence layer. Together, they give companies a foundation for AI that does more than answer questions. CollectivIQ’s ecosystem can learn how an organization works, retain what it learns and make that knowledge useful across the enterprise.

GigaBrain is available through the CollectivIQ platform. For more information, visit www.collectiviq.ai.

About CollectivIQ

CollectivIQ is the collective intelligence platform built to give employees more accurate AI insights and teammates that put its intelligence to work. Founded by the leadership team behind Buyers Edge Platform, CollectivIQ was built to bring accountability, action, and economic alignment to enterprise AI adoption. Learn more at www.collectiviq.ai.

View original content to download multimedia:https://www.prnewswire.com/news-releases/collectiviq-introduces-gigabrain-giving-enterprises-a-shared-brain-that-gets-smarter-as-employees-work-302915537.html

SOURCE CollectivIQ

Continue Reading

Technology

Pactum Launches Intake Agent, Cutting Purchase Request Cycle Time by 90%

Published

on

By

New AI agent replaces complicated purchase forms and repeated follow-ups by completing and checking every request before it is submitted, inside Microsoft Teams, Coupa, and SAP Ariba.

MOUNTAIN VIEW, Calif., Oct. 21, 2026 /PRNewswire/ — Pactum, the most advanced agentic AI platform for enterprise autonomous procurement execution, today announced the launch of its Intake Agent, which lets employees describe what they need to buy in plain language. The agent turns each request into a complete, correctly coded requisition and checks it against company buying policies before it is submitted.  Available now in Microsoft Teams, Coupa, and SAP Ariba, the Intake Agent connects with Pactum’s other agents to enable end-to-end autonomous indirect procurement. A purchase can draw on an existing contract or move to autonomous sourcing and negotiation, with a human buyer handling requests that require judgment.

The launch extends Pactum’s growing portfolio of AI agents to the start of indirect procurement, covering purchases such as software, office equipment, and professional services. It brings Pactum’s co-founders’ vision of procurement run with AI agents from the first request through sourcing and negotiation into operation. Procurement teams set the buying rules once, and the agent applies them to every request, whatever its value.

“Procurement teams can now run indirect procurement with full autonomy while remaining in control and managing the exceptions,” said Kaspar Korjus, Co-Founder and CEO of Pactum. “Our Intake Agent helps resolve questions earlier so requests can move forward with less back-and-forth and teams can focus on the decisions that need their expertise.”

For employees, finding an approved supplier or selecting the right accounting code can require expertise across procurement, finance, operations, and IT teams. Missing or incorrect information can lead to rejected requisitions and repeated follow-ups, leaving buyers to focus on correcting forms instead of focusing on supplier relationships and commercial decisions. Review queues can stretch from days to weeks.

With Pactum Intake, employees describe what the business needs, whether goods or services of any complexity, and can provide supporting documents such as a supplier quote. The agent uses the request and relevant documents to identify the best procurement category and complete the accounting and supplier details. It asks only the follow-up questions needed to complete the requisition. Once the request is checked, it is handed off to another Pactum digital worker to autonomously source and negotiate for better pricing and terms where required.

“Building software that assists procurement professionals is relatively easy. Building software that runs the whole process on its own, from the first request to the final purchase, is much harder,” said Kristjan Korjus, Co-Founder and Chief Scientist at Pactum. “It is the difference between driver assistance and a car with no one behind the wheel. Most procurement AI still needs a buyer at the wheel for every request. Our AI agents take the request all the way to the purchase on their own, and it is remarkable to watch them pass the work from one agent to the next.”

The launch follows Pactum’s Requisition Alignment Agent surpassing one million requisition checks, which validates purchase requests against company buying policies, existing contracts, and approved suppliers. Intake builds on this foundation in policy enforcement by connecting employee requests with agents that carry out sourcing and negotiation.

For more information about Pactum Intake, visit https://pactum.com/procurement-agents/intake.     

About Pactum:

Since 2019, Pactum has been leading the shift to autonomous procurement. Its AI agents check every purchase request against a company’s policies, contracts and approved suppliers, source and negotiate with suppliers in more than 40 languages, and work inside Coupa and SAP Ariba. Pactum agents are relied on by more than 60 of the world’s largest enterprises. To learn more, visit www.pactum.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pactum-launches-intake-agent-cutting-purchase-request-cycle-time-by-90-302915539.html

SOURCE Pactum

Continue Reading

Technology

Crush Security Launches Crush Dollar Exposure, Turning Cyber Risk Into Dollars and Showing Which Security Investments Reduce It Most

Published

on

By

New financial risk intelligence capability uses FAIR-informed modeling, Monte Carlo analysis and security data to help CISOs and CFOs quantify cyber exposure, prioritize remediation and communicate financial risk to executive leadership.

SCOTTSDALE, Ariz., Oct. 21, 2026 /PRNewswire/ — Crush Security today announced the launch of Crush Dollar Exposure, a new capability within its cybersecurity intelligence platform that translates cyber risk into financial exposure and helps organizations identify which security improvements can deliver the greatest reduction in potential financial loss.

For years, cybersecurity teams have measured their environments through vulnerabilities, risk scores, compliance percentages and control gaps. While valuable to security operations, those measurements often fail to answer the fundamental questions that executives and boards need answered:

How much could our cybersecurity weaknesses cost the business, and where should we invest to reduce that exposure?

Crush Dollar Exposure is designed to answer those questions by connecting an organization’s security posture, control coverage, threat intelligence and industry financial loss data to a quantitative view of cyber risk. The result is a financial perspective that enables security and business leaders to evaluate potential losses, compare remediation priorities and make more informed investment decisions.

From Technical Risk Scores to Financial Decisions

Traditional cybersecurity assessments often produce long lists of findings ranked by technical severity. But the most technically severe vulnerability is not necessarily the one that represents the greatest potential financial loss to the organization.

Crush Dollar Exposure changes the decision-making process by evaluating security gaps through their estimated contribution to financial risk. The capability provides four principal measurements:

Annualized Financial Exposure: An estimate of potential annual cyber losses, expressed in dollars.Financial Exposure Relative to Revenue: A view of modeled cyber exposure in relation to the organization’s annual revenue, providing business context.Value-at-Risk Analysis: Potential loss thresholds at selected probability levels, supported by loss-exceedance curves that illustrate the range of possible financial outcomes.Financially Prioritized Remediation: Security control gaps ranked by their modeled contribution to financial exposure, helping teams identify where remediation may reduce the most risk.

Rather than simply reporting that a security control is missing or a vulnerability is critical, Crush Dollar Exposure helps organizations understand the potential financial consequences and prioritize corrective action accordingly.

Connecting Every Security Gap to Business Impact

One of the capability’s key differentiators is its ability to connect security control weaknesses to modeled loss scenarios and financial consequences.

For example, a security team evaluating investments in identity protection, endpoint security and vulnerability remediation can use the model to determine which weaknesses contribute most significantly to estimated financial exposure. This allows security leaders to move beyond asking which problem is technically most severe and begin asking which investment is likely to provide the greatest financial risk reduction.

The analysis also connects control gaps to underlying loss scenarios, helping organizations understand how multiple weaknesses may contribute to the same business risk. For CFOs and executive teams, this provides a more financially grounded way to evaluate cybersecurity spending. For CISOs, it creates a defensible framework for explaining security priorities and communicating their potential business impact.

Transparent, Reproducible Risk Modeling — Not a Black-Box AI Score

Crush Dollar Exposure uses a quantitative methodology informed by the Factor Analysis of Information Risk (FAIR) framework and Monte Carlo simulation to model possible financial losses.

The methodology incorporates security control coverage, industry-relevant threat activity, recognized adversary techniques, organizational characteristics and established financial loss reference data.

Unlike opaque risk-scoring approaches, the capability is designed to make the assumptions, data inputs and modeled loss scenarios underlying its financial estimates visible and reviewable. Although Crush Security’s broader platform includes Cassandra, its AI-powered security advisor, the financial risk calculations themselves rely on defined quantitative modeling rather than generative AI.

The capability distinguishes between uncertainty in modeled financial outcomes and confidence in the quality of supporting data, helping executives understand both the estimated exposure and the limitations of the underlying analysis. This transparency is intended to support repeatable analysis, auditability and more defensible conversations with boards, regulators and financial stakeholders.

Giving CISOs and CFOs a Common Language

“Cybersecurity leaders are constantly asked to justify their budgets, but we’re still presenting information to boards that doesn’t directly answer the questions they’re asking,” said Josh Jones, CEO and Co-Founder of Crush Security. “Boards don’t just want to know how many vulnerabilities you have or how many security tools you’ve deployed. They want to understand what the risk could cost the business, where their money is going, and whether those investments are making a measurable difference.”

“With Crush Dollar Exposure, we’re connecting cybersecurity decisions to financial outcomes. Our goal is to give every CISO the ability to walk into a board meeting and explain their organization’s estimated financial exposure, identify the gaps driving it, and show which actions have the greatest potential to reduce that risk.” -Joshua Jones, CEO-

Built on the Crush Security Intelligence Platform

Crush Dollar Exposure extends Crush Security’s intelligence platform, which brings together vendor, control, compliance and threat data to support security investment decisions.

Powered by Cassandra, the platform helps organizations identify coverage gaps, compare technology and vendors, and optimize cybersecurity spending.

Risk calculations are performed within each customer’s data environment, with customer-specific information remaining within its designated security boundary. Anonymized and aggregated industry reference information supports comparative risk modeling.

Availability

Crush Dollar Exposure is available now within the Crush Security platform. Organizations interested in quantifying their financial cyber exposure, evaluating remediation priorities or scheduling a demonstration can visit www.CrushSecurity.com. Access information is available directly from Crush Security.

About Crush Security

Crush Security is a veteran-owned cybersecurity technology and advisory company headquartered in Scottsdale, Arizona.

Its proprietary intelligence platform, advisory services and cybersecurity procurement data help customers make data-driven technology purchasing decisions leveraging Crush Security’s resell capabilities.

Cassandra, its AI-powered advisor, unifies security, vendor and compliance intelligence to identify gaps, optimize investments, quantify risk and evaluate solutions to shorten the decision time and accuracy for each project.

Crush Security’s core intelligence platform is currently included at no separate subscription cost with eligible customer engagements.

Website: www.CrushSecurity.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/crush-security-launches-crush-dollar-exposure-turning-cyber-risk-into-dollars-and-showing-which-security-investments-reduce-it-most-302914088.html

SOURCE Crush Security Group Inc

Continue Reading

Trending